QuarterHawk — Equity ResearchQuarterHawk — Equity Research

QuidelOrtho Corporation (QDEL)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3 (shadow sum-gate unavailable — flag false), so no bullish entry is admissible; the chart is broken anyway (10.74 below SMA20 12.98, SMA50 12.31 and SMA200 15.38 with MACD -0.46), no pullback limit qualifies because it would be countertrend (price < SMA50 with MACD < 0, and the 50-day sits below a 200-day at 15.38 with no reclaim), and no breakout stop qualifies (technicalScore 1 < 3, and a trigger above the settled 12.21 high would sit inside the falling SMA20/SMA50 supply band).

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

QuidelOrtho Corporation develops and manufactures diagnostic testing solutions across several healthcare segments. Its Labs division offers clinical chemistry and immunoassay tests, while the Transfusion Medicine unit provides blood safety screening. The company also delivers rapid diagnostic tests through its Point-of-Care segment and advanced molecular diagnostic tools. Founded in 1979, QuidelOrtho operates globally, including in North America, Europe, and China.

Fundamental

weak
Fundamental2
Strained fundamentals

QuidelOrtho faces high leverage and negative cash flow, with goodwill impairments overstating losses but cash flow confirming financial strain.

Leveraged, cash-consuming diagnostics turnaround: Q3 2026 revenue fell 11.6%, nine-month operating cash flow was -$124.0M and free cash flow -$202.8M, with $2.94B of borrowings against roughly $540M of adjusted EBITDA and covenants reset in September 2026 to 5.50x leverage / 2.25x coverage with little headroom. Goodwill impairments explain most of the GAAP losses, but negative cash flow confirms the strain. Consensus target of about $12.25 offers modest upside; the risk profile stays elevated until cash generation turns positive.

Sentiment

weak
Sentiment2
Deteriorating sentiment

Sentiment has worsened following a revenue miss and narrowed guidance, with no positive catalysts in the near term.

Q3 2026 results (2026-11-03, confidence: announced) are the dominant catalyst and they are bearish on market reception — revenue of $618.9M missed the $627.8M FactSet consensus, FY2026 revenue guidance was narrowed with adjusted EPS guidance lowered, and shares fell 10.6%–14%, leaving a determinate sentiment deterioration (baseline −0.05 → scoring −0.32) with no forward-dated offset anywhere in the 30-day horizon. No severe red flag fired, but a moderate flag fired for sharp 14-day sentiment deterioration with no offsetting bullish catalyst and the moderate red-flag cap was applied; retail sentiment is unreadable because Reddit access was blocked.

Technical

very weak
Technical1
Downtrend continuation

The stock is in a downtrend, trading below key moving averages with negative momentum indicators.

QDEL's chart is broken, not basing. At 10.74 the stock trades below its SMA20 (12.98), SMA50 (12.31), SMA200 (15.38) and every short-term average in the stack (EMA9 11.83, EMA21 12.46, WMA9 11.53, WMA21 12.53, DEMA14 11.51), with only TEMA14 (10.87) marginally above price. MACD is negative on all three readings (-0.46 line / -0.10 signal / -0.36 histogram) with the histogram widening negative, confirming downside momentum. RSI14 39.00 and Williams %R -89.93 are oversold, but ADX14 23.67 and rising while price sits under the entire moving-average stack reads as a developing downtrend rather than accumulation — ADX is direction-agnostic and must be read with price below all MAs. ATR14 1.21 (11.27% of price) and StdDev20 1.23 describe a violent tape, and the post-earnings sequence — 14.35 on 2026-11-04 down to 10.70 on 2026-11-06, a failed bounce to 12.09 (11-09) and 11.91 (11-11), then a fade back to 10.74 — shows persistent supply, not a floor; the 2026-11-13 session was a 0.91-range doji closing 10.74 against a 10.72 VWAP in the year-low area (year low 9.92). technicalScore 1 reflects a bearish, structurally broken chart. Independent of the chart, the trade is inadmissible: fundamentalScore 2 and qualitativeScore 2 both fail the ≥3 override floor, and the shadow sum-gate is unavailable because the shadow flag is false.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.